A study on the treatment of Parkinson's disease and cognitive impairment with multiple system atrophy by intranasal injection of insulin

Abstract

Parkinson's disease (PD) and multiple system atrophy (MSA) are both common neurodegenerative diseases. To investigate the effects of intranasal insulin injection on motor function and cognitive impairment in patients with Parkinson's disease (PD) and multiple system atrophy (MSA).Thirteen PD patients and one MSA patient participated in the experiment . Using a random number table method, the participants were assigned to an experimental group (n=8) and a control group (n=6). The experimental group received insulin injection, while the control group received physiological saline injection. Both groups received nasal injection for 4 consecutive weeks. Compare the general information, language fluency (FAS), Montreal Cognitive Assessment Scale (MoCA), Beck Depression Inventory (BDI), and Parkinson's Unified Rating Scale (UPDRS) results between the two groups. Compared to the control group, the experimental group had a significantly higher FAS score, but there was no significant difference in the FAS score before and after treatment in the experimental group, and the prognosis score improved compared to before. In the experimental group, a MSA patient showed improvement in FAS scores during the four week treatment period, with no significant progression of the disease. There was no significant improvement in UPDRS score, BDI score, and MoCA score before and after treatment, the difference was not significant statistically. The use of insulin therapy for cognitive and motor disorders related to PD is safe and feasible. Intranasal insulin may improve functional motor function and cognitive performance in Parkinson's disease.